Midday movers: Victoria's Secret, Nordstrom fall; OneSpan, Novo Nordisk rise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Midday movers: Victoria's Secret, Nordstrom fall; OneSpan, Novo Nordisk rise
March 11, 2024 2:03 PM EDT
TD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.
The analyst comments "Novo announced FDA approval of the expanded label for Wegovy, now indicated to reduce CV risk in people with both obesity and CVD based on data from SELECT. Though these data are widely appreciated by specialists after... More
March 11, 2024 3:59 AM EDT
BMO Capital analyst Kelly Bania raised the price target on Kroger (NYSE: KR) to $58.00 (from $46.00) while maintaining a Market Perform rating.
The analyst comments "KR's F4Q24 performance was solid and guidance suggests environment remains stable, which we believe combined with positive... More
March 8, 2024 9:35 AM EST
BofA Securities analyst Robert Ohmes raised the price target on Kroger (NYSE: KR) to $70.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "Post KR's strong F4Q earnings, we reiterate our Buy rating. We raise our PO to $70 (was... More
March 7, 2024 4:30 PM EST
Jefferies analyst Corey Tarlowe lowered the price target on Victoria's Secret (NYSE: VSCO) to $27.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "VSCO reported 4Q results within its guided range. The top line came in just shy of expectations, but better-than-expected gross... More
March 7, 2024 4:06 PM EST
Stifel analyst Stephen Gengaro reiterated a Buy rating and $18.00 price target on Rivian Automotive Inc (NASDAQ: RIVN).
The analyst comments "Rivian unveiled its R2 mid-size SUV platform earlier today, expected to start at about $45,000 and scheduled for initial production in 1H26. Key positives from the launch... More
March 7, 2024 1:59 PM EST
Jefferies initiated Viking Therapeutics (NASDAQ: VKTX) with a Buy rating and $110 per share price target in a note Thursday, telling investors the company is a strong mid-stage obesity player with scarcity value.
VKTX is developing subQ/oral VK2735 (GLP-1/GIP) for obesity,... More
